{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RSV+MAT",
    "query": {
      "intervention": "RSV MAT"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T15:06:30.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04980391",
      "title": "A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 49 Years · Female only"
      },
      "enrollment_count": 384,
      "start_date": "2021-08-03",
      "completion_date": "2023-05-30",
      "has_results": true,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980391"
    },
    {
      "nct_id": "NCT03674177",
      "title": "A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "GSK3888550A RSV Maternal vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK3888550A RSV Maternal vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK3888550A RSV Maternal vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Normal Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 502,
      "start_date": "2018-10-30",
      "completion_date": "2019-09-02",
      "has_results": true,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Rochester, New York",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03674177"
    },
    {
      "nct_id": "NCT05229068",
      "title": "A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2022-03-11",
      "completion_date": "2024-10-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 2,
      "location_summary": "Missoula, Montana • Norfolk, Nebraska",
      "locations": [
        {
          "city": "Missoula",
          "state": "Montana"
        },
        {
          "city": "Norfolk",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05229068"
    },
    {
      "nct_id": "NCT04126213",
      "title": "Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT 60 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV MAT 120 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 534,
      "start_date": "2019-11-05",
      "completion_date": "2021-05-14",
      "has_results": true,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126213"
    },
    {
      "nct_id": "NCT05169905",
      "title": "A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "dTpa vaccine",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 49 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2022-02-02",
      "completion_date": "2022-08-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Beaumont, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Beaumont",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169905"
    },
    {
      "nct_id": "NCT05045144",
      "title": "A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3(120 μg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Flu Quadrivalent influenza vaccine (15 μg HA)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1586,
      "start_date": "2021-10-26",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 5,
      "location_summary": "West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045144"
    },
    {
      "nct_id": "NCT04605159",
      "title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 11194,
      "start_date": "2020-11-20",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605159"
    },
    {
      "nct_id": "NCT05705440",
      "title": "A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 49 Years · Female only"
      },
      "enrollment_count": 3855,
      "start_date": "2023-02-07",
      "completion_date": "2025-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-06T15:06:30.431Z",
      "location_count": 27,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05705440"
    }
  ]
}